Tanaka E, Kiyosawa K, Matsumoto A, Sodeyama T, Urushihara A, Suzuki T, Kobayashi M, Furuta S
Second Department of Internal Medicine, Shinshu University School of Medicine, Nagano.
Jpn J Med Sci Biol. 1994 Feb;47(1):47-57. doi: 10.7883/yoken1952.47.47.
Hepatitis C virus (HCV) genotypes (groups I and II) were determined by a newly developed C14 assay in which antibodies against group-specific recombinant proteins of the NS4 region were measured by ELISA (enzyme-linked immunosorbent assay). The genotypes determined by the C14 assay were compared to those determined by a polymerase chain reaction (PCR) in 50 patients. The HCV genotypes determined by both methods were consistent in 78% of the patients. The results of the assays were not contradictory in any patient. The sensitivity of the C14 assay was as high as over 90%. Frequency of HCV genotypes was studied in 300 patients with chronic liver diseases type C by using the C14 assay. The prevalence of groups I and that of II in patients with chronic hepatitis were 73% and 21%, the correspondence figures in those with liver cirrhosis 80% and 13%, and in those with hepatocellular carcinoma 81% and 13%, respectively. The clinical characteristics were similar between the patients with group I and II HCV infections in each disease category. In conclusion, the C14 assay is useful for epidemiological studies of HCV genotypes, and group I is a major HCV genotype of chronic liver diseases type C in Japan.
通过一种新开发的C14检测法来确定丙型肝炎病毒（HCV）基因型（I组和II组），该检测法通过酶联免疫吸附测定（ELISA）来检测针对NS4区域组特异性重组蛋白的抗体。将50名患者中通过C14检测法确定的基因型与通过聚合酶链反应（PCR）确定的基因型进行比较。两种方法确定的HCV基因型在78%的患者中是一致的。在任何患者中，检测结果都不相互矛盾。C14检测法的灵敏度高达90%以上。通过使用C14检测法，对300例慢性丙型肝病患者的HCV基因型频率进行了研究。在慢性肝炎患者中，I组和II组的患病率分别为73%和21%，在肝硬化患者中分别为80%和13%，在肝细胞癌患者中分别为81%和13%。在每个疾病类别中，I组和II组HCV感染患者的临床特征相似。总之，C14检测法对HCV基因型的流行病学研究有用，并且I组是日本慢性丙型肝病的主要HCV基因型。
